Editas Medicine (EDIT) Enterprise Value (2015 - 2025)

Editas Medicine (EDIT) has 11 years of Enterprise Value data on file, last reported at -$146.6 million in Q4 2025.

• On a quarterly basis, Enterprise Value rose 45.67% year-over-year to -$146.6 million in Q4 2025; TTM through Dec 2025 was -$146.6 million, a 45.67% increase from a year earlier, with the FY2025 full-year figure at -$146.6 million, up 45.67% from the prior year.
• Enterprise Value for Q4 2025 stood at -$146.6 million, up from -$165.6 million in the prior quarter.
• Over the last five years, Enterprise Value for EDIT reached as high as -$146.6 million in Q4 2025 and fell as low as -$625.3 million in Q1 2021.
• Historically, Enterprise Value has averaged -$362.2 million across 5 years, with a median of -$333.7 million in 2022.
• Across the five-year window, Enterprise Value tumbled 50.69% in 2021 and jumped 45.67% in 2025, its largest moves.
• Year by year, Enterprise Value stood at -$499.8 million in 2021, then soared by 31.12% to -$344.3 million in 2022, then gained by 6.15% to -$323.1 million in 2023, then advanced by 16.46% to -$269.9 million in 2024, then soared by 45.67% to -$146.6 million in 2025.
• Per Business Quant data, the three most recent Enterprise Value figures were -$146.6 million in Q4 2025, -$165.6 million in Q3 2025, and -$178.5 million in Q2 2025.